Compare Caesars Entertainment Inc (CZR) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Caesars Entertainment Inc trades at $29.52 (market cap $6.02B), while Nuvation Bio Inc. Class A Common Stock trades at $5.03 (market cap $1.74B). The key difference: Caesars Entertainment Inc is far larger — about 3.5× Nuvation Bio Inc. Class A Common Stock's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| CZR | NUVB | |
|---|---|---|
Market Cap | $6.02B | $1.74B |
Volume | 6,412,151 | 9,289,619 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $9.54 |
52-Week Low | $18.14 | $3.41 |
Typical Hold Time | 31 Days | 1 Days |
Enterprise Value | $29.91B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $29.54, showing minimal daily movement with a 0.15% gain. The stock faces bearish technical signals and has missed earnings expectations for three consecutive quarters, with negative profitability metrics including -3.99% net income margin. The pending $31 per share acquisition by Fertitta Entertainment provides a potential floor, while recent news highlights shareholder investigations into the deal's fairness. Cash flow trends show improvement with net cash flow narrowing from -$689M in 2022 to -$32M in 2025.
CZR presents a mixed outlook with acquisition upside limited to 5% from current levels, offset by fundamental challenges including consistent earnings misses and negative margins. Key risks include merger uncertainty and high debt load, while analyst sentiment remains cautious with 68% hold ratings. The stock offers speculative appeal for merger arbitrage but lacks organic growth catalysts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
